Phase 2 N=40 Pharmacological Ascorbate for Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Tumor Response — 13; 19; 5; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=103 ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Prostate Cancer Metastatic · Castration-resistant Prostate Cancer
Primary: Radiographic Progression Free Survival (rPFS) — 11.1; 9.5 Months — p=0.1465
Phase 2 N=17 Letrozole for Lymphangioleiomyomatosis
Lymphangioleiomyomatosis
Primary: Rate of Change in Forced Expiratory Volume in 1 Second in ml/Month — 1.04; 1.66 milliliters per month — p=0.4
N/A N=6 Virtual Reality Biofeedback for Postpartum Anxiety and Depression
Anxiety and Depression · Postpartum Depression · Pregnancy Related
Primary: Intervention Feasibility — 4.83 score on a scale
Phase 2 N=64 CBD for Dental Pain
Odontalgia · Toothache
Primary: Intra-group VAS Pain Intensity and Maximum Pain Relief — 63; 69; 63; 21 score on a scale
N/A N=81 Knotless Suture in Revision Total Joint Arthroplasty
Arthroplasty
Primary: Time of Closure in Minutes — 36.3; 31.1; 35.9; 27.1 minutes
Phase 2 N=147 Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
Depressive Disorder, Major
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2) — -26.2; -29.6; -31.8; -30.3 Units on a scale…
N/A N=101 Water-based Activity to Enhance Recall in Veterans
Mild Cognitive Impairment
Primary: Retention and Recruitment Rates — 21 Participants
Phase 2 N=49 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Graft Vs Host Disease · Graft-versus-host-disease · Acute-graft-versus-host Disease
Primary: Grades II-IV aGVHD — 11 Participants
Phase 2 N=69 A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
Essential Tremor
Primary: Change From Baseline Compared to Placebo in TETRAS Performance Subscale Part 4 Upper Limb Tremor Score on Day 29 — -2.31; -1.24 score on a scale — p=0.0491
N/A N=20 To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
Inflammation
Primary: Change in CD68 mRNA Expression in MNC — 10; -68 percentage of change
N/A N=48 Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV
HIV Infections · Health Behavior
Primary: Feasibility Intervention Measure — 18 units on a scale
Phase 2 N=471 Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
Influenza · Human
Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HI) Assay and Against…
N/A N=21 The Aortix CRS Pilot Study
Heart Failure; With Decompensation · Cardiorenal Syndrome · Cardio-Renal Syndrome
Primary: Serious Adverse Events — 18 Events
N/A N=128 SPYRAL DYSTAL Renal Denervation Global Clinical Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Change in Systolic Blood Pressure (SBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) — -16.6 mmHg